FGF1 and cancer: In this study, we engineered the FGF1 ligand and radiolabeleditwith 161Tb for targeting FGFR-overexpressing cancer cells.The eFGF1 vector was engineered to allow site-specific conjugationof maleimide-DOTA and chelation of the 161Tb radionuclide.Site-specific labeling was chosen to avoid conflict of the conjugationto binding of the ligand to its receptor.